An interventional study of Continuous glucose monitoring (CGM) in End Stage Kidney Disease, sponsored by Emory University. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-05.
Sponsored by Emory University · Not applicable, Interventional, and Supportive care
Twenty participants with end stage kidney disease (ESKD) and burnt-out diabetes, and 20 non-diabetic participants with ESKD will wear a continuous glucose monitoring (CGM) device for 10 days to see if the use of CGM is a better tool to assess glycemic control than glycosylated hemoglobin (HbA1c) in patients with ESKD on dialysis.
More than 37 million adults, or 14.7% of all Americans aged 18 and older, are living with diabetes. Controlling hyperglycemia is foundational to diabetes management and is necessary to reduce the risks of chronic diabetes complications and death. Diabetic nephropathy accounts for great morbidity, as diabetes is the number one cause of chronic kidney disease (CKD) and end stage kidney disease (ESKD) in the United States. It is estimated that diabetes affects up to 40% of patients with ESKD.
Assessment of glucose control in patients with advanced CKD/ESKD is complex due to changes in glucose homeostasis, potential effects on assays of glycemia, and altered pharmacokinetics of diabetes medications. Glycosylated hemoglobin (HbA1c) has been the gold standard to assess glycemic control in patients with diabetes. HbA1c reflects the average glycemic value over approximately 3 months. Although HbA1c is associated with chronic complications of diabetes in patients with normal kidney function, its predictive value is uncertain in patients with ESKD or estimated glomerular filtration rate (eGFR) \<30 ml/min. HbA1c reliability in ESKD is reduced because of anemia, shortened erythrocyte lifespan, protein-energy wasting, and malnutrition-inflammation cachexia syndrome, among others. To overcome the limitations of HbA1c, alternative methods to assess long-term glycemic control have been proposed including fructosamine and glycated albumin. Fructosamine measures ketoamines formed by non-enzymatic glycation of serum proteins. It is a useful index for glycemic control over the prior 2 to 4 weeks, and some studies have reported that fructosamine more accurately reflects blood glucose control than HbA1c in anemic patients with ESKD on dialysis. However, there may be falsely low readings in the presence of hypoalbuminemia due to protein-energy wasting and in peritoneal dialysis due to dialysate protein loss. Glycated albumin is a useful marker reflecting glycemic control over the prior 2 to 4 weeks. In patients with ESKD, glycated albumin more rapidly reflects the status of blood glucose control than HbA1c. Like fructosamine, there is potential for falsely low readings in patients with peritoneal dialysis with dialysate protein losses and hypoalbuminemia.
Continuous glucose monitoring (CGM) technology in the outpatient setting has transformed glucose monitoring for diabetes self-management, providing more comprehensive glycemic control data than intermittent point-of-care capillary blood glucose monitoring and HbA1c.
Once progressed to ESKD, up to one fourth of patients experience resolution of their hyperglycemia, as defined by an HbA1c level of less than 6.5%, and consequently are no longer on antidiabetic agents and insulin. This phenomenon is known as "burnt-out diabetes" which is likely due to various underlying factors, including but not limited to, malnutrition, reduced clearance and degradation of insulin, decreased kidney gluconeogenesis, and accumulation of uremic toxins. These patients are likely at a greater risk of morbidity and mortality and an increased risk of hypoglycemic episodes. There is a need for further research in patients with ESKD to establish what is the most appropriate tool to assess glycemic control in those with 'burnt-out diabetes'.
This study will use CGM to measure patients' glucose with real-time levels as opposed to relying on surrogate markers like HbA1c. These results can give insight into the reality of glycemic control in these patients and can impact the best monitoring and treatment for patients with burnt-out diabetes. It is not known if patients with burnt-out diabetes have complete normoglycemia or if they may have episodes of (untreated) hyperglycemia, which may be associated with poor outcomes. The researchers of this study will compare glycemic control by CGM in patients with burnt-out diabetes and non-diabetic patients with ESKD.
3,840 studies on the registry are indexed under Kidney Diseases; 500 are open to participants now.
This study's enrollment of 40 is below the median of 70 across 2,640 interventional studies indexed under Kidney Diseases.
Browse Kidney Diseases studies →Emory University is the lead sponsor of 1,386 studies on the registry; 236 are open to participants now.
Of its 229 completed or terminated interventional studies of FDA-regulated products, 174 (76%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Participants with ESKD and burnt-out diabetes wearing a CGM for 10 days.
Device: Continuous glucose monitoring (CGM)
Non-diabetic participants with ESKD wearing a CGM for 10 days.
Device: Continuous glucose monitoring (CGM)
The Dexcom G6 CGM system is a compact, light-weight glucose testing device that measures glucose every 5 minutes. Participants will wear the CGM with the display off for 10 days while continuing their routine dialysis sessions.
Also known as: Dexcom G6 CGM
Percent of Time in Range (TIR) Between 70-180 mg/dL
Glycemic control is measured as the percentage of time that blood glucose levels are in the range of 70 and 180 mg/dL, as measured by CGM.
Time frame: Up to 10 days
Percent of Time Above Range (Blood Glucose >180 mg/dL)
Glycemic control is assessed a the percentage of time in hyperglycemia, defined as the time above range (TAR) with blood glucose measurements \>180 mg/dL, as measured by CGM.
Time frame: Up to 10 days
Percent of Time Above Range (Blood Glucose >250 mg/dL)
Glycemic control is assessed a the percentage of time in hyperglycemia, defined as the time above range (TAR) with blood glucose measurements \>250 mg/dL, as measured by CGM.
Time frame: Up to 10 days
Duration of Hyperglycemia (Blood Glucose >180 mg/dL)
Glycemic control is assessed as the duration of hyperglycemia with blood glucose measurements \>180 mg/dL, as measured by CGM for hyperglycemia time periods of greater than 15 minutes.
Time frame: Up to 10 days
Duration of Hyperglycemia (Blood Glucose >250 mg/dL)
Glycemic control is assessed as the duration of hyperglycemia with blood glucose measurements \>250 mg/dL, as measured by CGM for hyperglycemia time periods of greater than 15 minutes.
Time frame: Up to 10 days
Number of Participants With Hyperglycemic Episodes With Blood Glucose >250 mg/dL
The number of participants experiencing hyperglycemia with blood glucose levels \> 250 mg/dL as measured by CGM.
Time frame: Up to Day 10
Percent of Time Below Range (Blood Glucose <70 mg/dL)
Glycemic control is assessed a the percentage of time in hypoglycemia, defined as the time below range (TBR) with blood glucose measurements \< 70 mg/dL, as measured by CGM.
Time frame: Up to 10 days
Percent of Time Below Range (Blood Glucose <54 mg/dL)
Glycemic control is assessed a the percentage of time in severe hypoglycemia, defined as the time below range (TBR) with blood glucose measurements \< 54 mg/dL, as measured by CGM.
Time frame: Up to 10 days
Hypoglycemia Event Rate
Hypoglycemia is defined as blood glucose \< 70 mg/dL and is assessed by Dexcom G6 CGM. The hypoglycemic event rate is defined as the number of hypoglycemic events per patient per day.
Time frame: Up to Day 10
Number of Participants With Hypoglycemic Episodes
The number of participants experiencing hypoglycemia with blood glucose levels \< 70 mg/dL as measured by CGM.
Time frame: Up to Day 10
Nocturnal Hypoglycemia Event Rate
Hypoglycemia is defined as blood glucose \< 70 mg/dL and is assessed by Dexcom G6 CGM. A nocturnal hypoglycemia episode is defined as an episode occurring during the time interval of 10:00 Post Meridiem (PM) to 6:00 Ante Meridiem (AM). The hypoglycemic event rate is defined as the number of hypoglycemic events per patient per day.
Time frame: Up to Day 10
Number of Participants With Nocturnal Hypoglycemic Episodes
The number of participants experiencing nocturnal hypoglycemia with blood glucose levels \< 70 mg/dL as measured by CGM. A nocturnal hypoglycemia episode is defined as an episode occurring during the time interval of 10:00 Post Meridiem (PM) to 6:00 Ante Meridiem (AM).
Time frame: Up to Day 10
Mean Daily Blood Glucose Concentration
Glycemic control is assessed as mean daily glucose concentration, measured by Dexcom G6 CGM.
Time frame: Up to Day 10
Glycemic Variability Calculated by Mean Amplitude of Glycemic Excursions (MAGE)
Mean amplitude of glycemic excursions (MAGE) is the parameter for assessing glycemic variability and is calculated based on the arithmetic mean of differences between consecutive peaks and nadirs of differences greater than one standard deviation (SD) of mean glucose values. It is designated to assess major glucose swings and exclude minor ones.
Time frame: Up to 10 Days
Participants were recruited from Emory Dialysis centers in Atlanta, Georgia, USA. Participant enrollment began August 10, 2022 and all follow-up assessments were completed by March 9, 2023.
| Milestone | End-Stage Kidney Disease (ESKD) With Burnt-out Diabetes | ESKD Without Diabetes |
|---|---|---|
| Started | 20 | 20 |
| Completed | 20 | 18 |
| Not completed | 0 | 2 |
Glycemic control is measured as the percentage of time that blood glucose levels are in the range of 70 and 180 mg/dL, as measured by CGM.
| percentage of time | ESKD With Burnt-out Diabetes | ESKD Without Diabetes |
|---|---|---|
| Percent of Time in Range (TIR) Between 70-180 mg/dL | 80.4 ± 14.0 | 94.0 ± 6.4 |
Glycemic control is assessed a the percentage of time in hyperglycemia, defined as the time above range (TAR) with blood glucose measurements \>180 mg/dL, as measured by CGM.
| percentage of time | ESKD With Burnt-out Diabetes | ESKD Without Diabetes |
|---|---|---|
| Percent of Time Above Range (Blood Glucose >180 mg/dL) | 17.2 ± 14.1 | 4.6 ± 5.3 |
Glycemic control is assessed a the percentage of time in hyperglycemia, defined as the time above range (TAR) with blood glucose measurements \>250 mg/dL, as measured by CGM.
| percentage of time | ESKD With Burnt-out Diabetes | ESKD Without Diabetes |
|---|---|---|
| Percent of Time Above Range (Blood Glucose >250 mg/dL) | 2.0 ± 3.0 | 0.1 ± 0.4 |
Glycemic control is assessed as the duration of hyperglycemia with blood glucose measurements \>180 mg/dL, as measured by CGM for hyperglycemia time periods of greater than 15 minutes.
| hours per day | ESKD With Burnt-out Diabetes | ESKD Without Diabetes |
|---|---|---|
| Duration of Hyperglycemia (Blood Glucose >180 mg/dL) | 4.1 ± 3.4 | 1.1 ± 1.3 |
Glycemic control is assessed as the duration of hyperglycemia with blood glucose measurements \>250 mg/dL, as measured by CGM for hyperglycemia time periods of greater than 15 minutes.
| hours per day | ESKD With Burnt-out Diabetes | ESKD Without Diabetes |
|---|---|---|
| Duration of Hyperglycemia (Blood Glucose >250 mg/dL) | 0.5 ± 0.7 | 0.1 ± 0.1 |
The number of participants experiencing hyperglycemia with blood glucose levels \> 250 mg/dL as measured by CGM.
| Participants | ESKD With Burnt-out Diabetes | ESKD Without Diabetes |
|---|---|---|
| Number of Participants With Hyperglycemic Episodes With Blood Glucose >250 mg/dL | 11 | 3 |
Glycemic control is assessed a the percentage of time in hypoglycemia, defined as the time below range (TBR) with blood glucose measurements \< 70 mg/dL, as measured by CGM.
| percentage of time | ESKD With Burnt-out Diabetes | ESKD Without Diabetes |
|---|---|---|
| Percent of Time Below Range (Blood Glucose <70 mg/dL) | 2.5 ± 5.8 | 1.5 ± 5.0 |
Glycemic control is assessed a the percentage of time in severe hypoglycemia, defined as the time below range (TBR) with blood glucose measurements \< 54 mg/dL, as measured by CGM.
| percentage of time | ESKD With Burnt-out Diabetes | ESKD Without Diabetes |
|---|---|---|
| Percent of Time Below Range (Blood Glucose <54 mg/dL) | 1.3 ± 3.5 | 0.4 ± 1.7 |
Hypoglycemia is defined as blood glucose \< 70 mg/dL and is assessed by Dexcom G6 CGM. The hypoglycemic event rate is defined as the number of hypoglycemic events per patient per day.
| events per patient per day | ESKD With Burnt-out Diabetes | ESKD Without Diabetes |
|---|---|---|
| Hypoglycemia Event Rate | 3.60 ± 7.37 | 3.44 ± 10.43 |
The number of participants experiencing hypoglycemia with blood glucose levels \< 70 mg/dL as measured by CGM.
| Participants | ESKD With Burnt-out Diabetes | ESKD Without Diabetes |
|---|---|---|
| Number of Participants With Hypoglycemic Episodes | 10 | 11 |
Hypoglycemia is defined as blood glucose \< 70 mg/dL and is assessed by Dexcom G6 CGM. A nocturnal hypoglycemia episode is defined as an episode occurring during the time interval of 10:00 Post Meridiem (PM) to 6:00 Ante Meridiem (AM). The hypoglycemic event rate is defined as the number of hypoglycemic events per patient per day.
| events per patient per day | ESKD With Burnt-out Diabetes | ESKD Without Diabetes |
|---|---|---|
| Nocturnal Hypoglycemia Event Rate | 1.30 ± 3.05 | 0.94 ± 2.86 |
The number of participants experiencing nocturnal hypoglycemia with blood glucose levels \< 70 mg/dL as measured by CGM. A nocturnal hypoglycemia episode is defined as an episode occurring during the time interval of 10:00 Post Meridiem (PM) to 6:00 Ante Meridiem (AM).
| Participants | ESKD With Burnt-out Diabetes | ESKD Without Diabetes |
|---|---|---|
| Number of Participants With Nocturnal Hypoglycemic Episodes | 7 | 4 |
Glycemic control is assessed as mean daily glucose concentration, measured by Dexcom G6 CGM.
| mg/dL | ESKD With Burnt-out Diabetes | ESKD Without Diabetes |
|---|---|---|
| Mean Daily Blood Glucose Concentration | 141.7 ± 22.2 | 125.7 ± 13.7 |
Mean amplitude of glycemic excursions (MAGE) is the parameter for assessing glycemic variability and is calculated based on the arithmetic mean of differences between consecutive peaks and nadirs of differences greater than one standard deviation (SD) of mean glucose values. It is designated to assess major glucose swings and exclude minor ones.
| mg/dL | ESKD With Burnt-out Diabetes | ESKD Without Diabetes |
|---|---|---|
| Glycemic Variability Calculated by Mean Amplitude of Glycemic Excursions (MAGE) | 54.9 ± 18.2 | 42.4 ± 9.4 |
Collected over Information on adverse events was collected beginning at the time individuals gave consent to participate in the study and continued up to Day 10.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ESKD With Burnt-out Diabetes | 0/20 (0%) | 0/20 (0%) | 0/20 (0%) |
| ESKD Without Diabetes | 0/20 (0%) | 0/20 (0%) | 0/20 (0%) |
| Age, Continuous(years) | ESKD With Burnt-out Diabetes | ESKD Without Diabetes | Total |
|---|---|---|---|
| Mean | 62.7 ± 8.3 | 60.1 ± 9.5 | 61.4 ± 8.9 |
| Sex: Female, Male(Participants) | ESKD With Burnt-out Diabetes | ESKD Without Diabetes | Total |
|---|---|---|---|
| Female | 10 | 8 | 18 |
| Male | 10 | 12 | 22 |
| Race (NIH/OMB)(Participants) | ESKD With Burnt-out Diabetes | ESKD Without Diabetes | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 20 | 20 | 40 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | ESKD With Burnt-out Diabetes | ESKD Without Diabetes | Total |
|---|---|---|---|
| United States | 20 | 20 | 40 |
| Coronary artery disease(Participants) | ESKD With Burnt-out Diabetes | ESKD Without Diabetes | Total |
|---|---|---|---|
| Count of participants | 7 | 3 | 10 |
| Heart failure(Participants) | ESKD With Burnt-out Diabetes | ESKD Without Diabetes | Total |
|---|---|---|---|
| Count of participants | 14 | 15 | 29 |
| Hypertension(Participants) | ESKD With Burnt-out Diabetes | ESKD Without Diabetes | Total |
|---|---|---|---|
| Count of participants | 20 | 18 | 38 |
| Hemoglobin A1c (HbA1c)(Participants) | ESKD With Burnt-out Diabetes | ESKD Without Diabetes | Total |
|---|---|---|---|
| < 5.7% | 10 | 13 | 23 |
| 5.7 to < 6.5% | 10 | 7 | 17 |
2 further baseline measures are reported on the registry.
Documents are hosted by the registry — open the source record to download them.
Plan to share: No
This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Emory University